SCHEMBL3857528

SCHEMBL3857528

[CH2]CCCCC#CCCCC

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN7 P35236 5/20 0.41
HMGCR P04035 3/20 0.41
TSHR P16473 2/20 0.39
RECQL P46063 2/20 0.39
TDP1 Q9NUW8 2/20 0.39
KDM4E B2RXH2 1/20 0.39
MEN1 O00255 1/20 0.39
USP2 O75604 1/20 0.39
ALDH1A1 P00352 1/20 0.39
POLB P06746 1/20 0.39
MAPT P10636 1/20 0.39
HPGD P15428 1/20 0.39
ALOX12 P18054 1/20 0.39
BLM P54132 1/20 0.39
KMT2A Q03164 1/20 0.39
MCL1 Q07820 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
RAB9A P51151 1/20 0.35
EPHX2 P34913 3/20 0.33
LMNA P02545 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3857022 0.97 PTPN7 (0.45) PTPN7HMGCRTSHRRECQLTDP1
SCHEMBL918335 0.97 PTPN7 (0.45) PTPN7HMGCRTSHRRECQLTDP1
SCHEMBL11264016 0.97 PTPN7 (0.45) PTPN7HMGCRTSHRRECQLTDP1
SCHEMBL313941 0.97 PTPN7 (0.45) PTPN7HMGCRTSHRRECQLTDP1
SCHEMBL7997996 0.97 PTPN7 (0.45) PTPN7HMGCRTSHRRECQLTDP1
SCHEMBL11044874 0.95 PTPN7 (0.43) PTPN7HMGCRTSHRRECQLTDP1
SCHEMBL3861223 0.94 PTPN7 (0.46) PTPN7HMGCRTSHRRECQLTDP1
SCHEMBL3868197 0.92 PTPN7 (0.50) PTPN7HMGCRTSHRRECQLTDP1
SCHEMBL8669383 0.92 PTPN7 (0.50) PTPN7HMGCRTSHRRECQLTDP1
SCHEMBL9681594 0.92 PTPN7 (0.50) PTPN7HMGCRTSHRRECQLTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024123801-A1 COMPOUNDS FOR TREATING CANCER GENESIS THERAPEUTICS, INC. (US) 2024-06-13 WO disclosed
EP-1756271-B1 METHODS FOR OBTAINING OPTICALLY ACTIVE EPOXIDES AND VICINAL DIOLS FROM 2,2-DISUBSTITUTED EPOXIDES CSIR (ZA) 2015-12-09 EP disclosed
EP-1753862-B1 METHODS FOR OBTAINING OPTICALLY ACTIVE EPOXIDES AND VICINAL DIOLS FROM MESO-EPOXIDES CSIR (ZA) 2015-11-18 EP disclosed
US-7591995-B2 Cobalamin conjugates useful as imaging and therapeutic agents MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2009-09-22 US disclosed
US-20090060837-A1 COBALAMIN CONJUGATES USEFUL AS ANTITUMOR AGENTS COLLINS DOUGLAS A 2009-03-05 US disclosed
US-7468432-B2 Cobalamin conjugates useful as antitumor agents MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2008-12-23 US disclosed
US-20080286832-A1 Methods for Obtaining Optically Active Epoxides and Vicinal Diols From 2,2-Disubstituted Epoxides COUNCIL FOR SCIENTIFIC AND INDUSTRIAL RESEARCH (ZA) 2008-11-20 US disclosed
WO-2008136850-A2 COBALAMIN CONJUGATES USEFUL AS IMAGING AND THERAPEUTIC AGENTS MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2008-11-13 WO disclosed
US-20080213833-A1 Methods for Obtaining Optically Active Glycidyl Ethers and Optically Active Vicinal Diols from Racemic Substrates OXRANE (UK) LTD. (GB) 2008-09-04 US disclosed
US-20080199912-A1 Methods for Obtaining Optically Active Epoxides and Diols from 2,3-Disubstituted and 2,3-Trisubstituted Epoxides OXYRANE (UK) LTD. (GB) 2008-08-21 US disclosed
EP-1171162-A2 COBALAMIN CONJUGATES USEFUL AS ANTITUMOR AGENTS MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2002-01-16 EP disclosed
US-6284784-B1 2-HYDROXYMETHYL DERIVATIVES GEORGETOWN UNIVERSITY 2001-09-04 US disclosed
WO-2001028595-A1 COBALAMIN CONJUGATES USEFUL AS IMAGING AND THERAPEUTIC AGENTS MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2001-04-26 WO disclosed
WO-2000062808-A2 COBALAMIN CONJUGATES USEFUL AS ANTITUMOR AGENTS MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2000-10-26 WO disclosed
EP-1015427-A1 SUBSTITUTED 2-PYRROLIDINONE ACTIVATORS OF PKC GEORGETOWN UNIVERSITY (US) 2000-07-05 EP disclosed
US-5962504-A ACTIVATOR OF PROTEIN KINASE; ANTICANCER AGENT GEORGETOWN UNIVERSITY (US) 1999-10-05 US disclosed
WO-1999012901-A1 SUBSTITUTED 2-PYRROLIDINONE ACTIVATORS OF PKC GEORGETOWN UNIVERSITY (US) 1999-03-18 WO disclosed
EP-0421441-B1 Pantothenic acid derivatives FUJIREBIO KK (JP) 1995-01-25 EP disclosed
US-5120738-A Cardiovascular disorders FUJIREBIO INC. (JP) 1992-06-09 US disclosed
EP-0421441-A2 Pantothenic acid derivatives FUJIREBIO INC. (JP) 1991-04-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080199912-A1 Methods for Obtaining Optically Active Epoxides and Diols from 2,3-Disubstituted and 2,3-Trisubstituted Epoxides EPHX2, ERG28, EPHX1 PTPN7 4861/4885HMGCR 1301/4885TSHR 4837/4885
US-20090060837-A1 COBALAMIN CONJUGATES USEFUL AS ANTITUMOR AGENTS MMAB, SLC19A2, SLC19A1 PTPN7 4190/4885HMGCR 760/4885TSHR 493/4885
US-20080213833-A1 Methods for Obtaining Optically Active Glycidyl Ethers and Optically Active Vicinal Diols from Racemic Substrates GALE, DERA, GNE PTPN7 4402/4885HMGCR 1834/4885TSHR 4775/4885
US-20080286832-A1 Methods for Obtaining Optically Active Epoxides and Vicinal Diols From 2,2-Disubstituted Epoxides EPHX2, ERG28, DERA PTPN7 4868/4885HMGCR 1703/4885TSHR 4863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.